Robert A Mckinney Net Worth

The estimated Net Worth of Robert A Mckinney is at least $390 Thousand dollars as of 3 October 2011. Robert Mckinney owns over 2,737 units of Progenics Pharmaceuticals stock worth over $192,249 and over the last 21 years Robert sold PGNX stock worth over $197,883.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Mckinney PGNX stock SEC Form 4 insiders trading

Robert has made over 43 trades of the Progenics Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert exercised 2,737 units of PGNX stock worth $12,645 on 3 October 2011.

The largest trade Robert's ever made was exercising 12,000 units of Progenics Pharmaceuticals stock on 1 August 2005 worth over $48,000. On average, Robert trades about 2,518 units every 51 days since 2003. As of 3 October 2011 Robert still owns at least 46,890 units of Progenics Pharmaceuticals stock.

You can see the complete history of Robert Mckinney stock trades at the bottom of the page.

What's Robert Mckinney's mailing address?

Robert's mailing address filed with the SEC is FOUR CATALPA DRIVE, , DANBURY, CT, 06811.

Insiders trading at Progenics Pharmaceuticals

Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch, and Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.

What does Progenics Pharmaceuticals do?

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Complete history of Robert Mckinney stock trades at Progenics Pharmaceuticals

Progenics Pharmaceuticals executives and stock owners

Progenics Pharmaceuticals executives and other stock owners filed with the SEC include:

• Partners, Llc Melkonian Cap...,
  
• Nicole Williams,
  Director
• Healthcare Master Fund Ltd ...,
  
• Healthcare Master Fund Ltd ...,
  
• Sheldon Hirt,
  Executive VP & General Counsel
• Michael D Kishbauch,
  Director
• David A Scheinberg,
  Director
• Karen Jean Ferrante,
  Director
• Peter J Crowley,
  Director
• Bradley L Campbell,
  Director
• Jeffery Summer,
  SVP, Digital Technology
• Patrick Fabbio,
  CFO
• Mark Robert Baker,
  CEO
• Charles A Baker,
  Director
• Kurt W Briner,
  Director
• Stephen P Goff,
  Director
• Mark F Dalton,
  Director
• Thomas A Boyd,
  SR. VP, Product Development
• Paul F Jacobson,
  Director
• Robert A Mckinney,
  VP of Finance and Admin
• Alton B Kremer,
  VP, Clinical Research
• Robert J Israel,
  Senior VP Medical Affairs
• Philip K Yachmetz,
  VP, Gen Counsel and Secretary
• Ronald J Prentki,
  President
• William C Olson,
  Senior VP, Research and Develo
• Paul J Maddon,
  Director
• Angelo William Jr Lovallo,
  Vice President Finance
• Hagop Youssoufian,
  Executive Vice President R&D
• Capital, L.P.Altiva Managem...,
  
• Heinz Christoph Maeusli,
  Director
• Gerard Ber,
  Director
• Ann L. Mac Dougall,
  Director
• Eric J Ende,
  Director
• Vivien Wong,
  EVP, Development
• David W. Mims,
  Interim CEO and Interim CFO
• Bryce Tenbarge,
  SVP, Commercial
• Benedict Osorio,
  COO
• Asha Das,
  Chief Medical Officer